Clotrimazole 1% — Competitive Intelligence Brief

Clotrimazole 1% (Clotrimazole 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Imidazole antifungal. Area: Infectious Disease.

marketed Imidazole antifungal Fungal cytochrome P450 (lanosterol 14α-demethylase) Infectious Disease Small molecule

Target snapshot

Clotrimazole 1% (Clotrimazole 1%) — Jinnah Postgraduate Medical Centre. Clotrimazole inhibits fungal cell membrane synthesis by blocking the conversion of lanosterol to ergosterol via inhibition of fungal cytochrome P450 enzymes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clotrimazole 1% TARGET	Clotrimazole 1%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Fungal cytochrome P450 (lanosterol 14α-demethylase)
Voriconazole clinical practice	Voriconazole clinical practice	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
fast itraconazole tablet	fast itraconazole tablet	University of Maryland, Baltimore	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
Voriconazole high dose	Voriconazole high dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
ORAL VORICONAZOLE and IV Amphotericin B	ORAL VORICONAZOLE and IV Amphotericin B	All India Institute of Medical Sciences	phase 3	Antifungal agents (triazole and polyene)	Fungal cytochrome P450 lanosterol 14α-demethylase (voriconazole); ergosterol (amphotericin B)
Monistat	miconazole	Johnson & Johnson (Janssen)	marketed	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Luliconazole Cream 1%	Luliconazole Cream 1%	Bausch Health Americas, Inc.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Imidazole antifungal class)

1. Galderma R&D · 2 drugs in this class
2. Bayer · 2 drugs in this class
3. AmDerma · 2 drugs in this class
4. Jinnah Postgraduate Medical Centre · 2 drugs in this class
5. Ache Laboratorios Farmaceuticos S.A. · 2 drugs in this class
6. Jamaica Hospital Medical Center · 1 drug in this class
7. Johnson & Johnson (Janssen) · 1 drug in this class
8. Laboratoire Innotech International · 1 drug in this class
9. PAEC General Hospital, Islamabad · 1 drug in this class
10. Peking University Shenzhen Hospital · 1 drug in this class